PDE5-IN-13
PDE5-IN-13 (Compound 14b) inhibits phosphodiesterase 5 (PDE5A) with an IC50 of 3 nM. PDE5-IN-13 is a potential candidate for PAH (pulmonary arterial hypertension) research. PDE5-IN-13 has high selectivity for targets over PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11. PDE5-IN-13 is orally active[1].
Product Specifications
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Smiles
C[C@@H](NC1=CC=CC(C(C2=CC=C(OC)C=C2)=C3C#N)=C1N(CC4=CC=CC=C4)C3=O)C5=CC=CC=N5
Molecular Formula
C31H26N4O2
Molecular Weight
486.56
References & Citations
[1]Zhang B, et.al. Discovery and Optimization of Dihydroquinolin-2 (1H) -ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. J Med Chem. 2024 Dec 26;67 (24) :22134-22144.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
PDE1; PDE10; PDE11; PDE2; PDE3; PDE4; PDE5; PDE6; PDE7; PDE8; PDE9
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
